Overview

Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma

Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
A Phase II clinical study to determine the efficacy of single agent Bendamustine for T cell lymphoma "BENTLY".
Phase:
Phase 2
Details
Lead Sponsor:
French Innovative Leukemia Organisation
Collaborator:
Mundipharma Pte Ltd.
Treatments:
Bendamustine Hydrochloride